Sequential Therapies After Osteoanabolic Treatment
ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50-85
Sponsor424 General Military Hospital
About this trial
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
Eligibility criteria
Qualifiers
None
Disqualifiers
a bone disease other than postmenopausal osteoporosis
use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study
creatinine clearance <60 mL/min/1.73 m2
liver failure
Trial design
Treatments tested in this trial
- Zoledronate
- Denosumab
- Teriparatide
- Romosozumab
- Abaloparatide Injection (80 mcg)
Treatment groups
150 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Locations
8Greece
, KAT General Hospital14561, Athens Greece
251 Airforce & VA General Hospital11525, Athens Greece
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens11527, Athens Greece
424 General Military Hospital56429, Thessaloniki Greece
Sponsors and collaborators
424 General Military Hospital
Lead sponsor
Source ClinicalTrials.gov